Cycle Pharmaceuticals to Purchase Applied Therapeutics
Acquisition Details: Applied Therapeutics has agreed to be acquired by Cycle Pharmaceuticals for $0.088 per share in cash, plus contingent value rights based on product approvals and sales milestones.
Cycle Pharmaceuticals' Focus: Cycle's pipeline targets rare genetic disorders, immunology, neurology, and oncology, with recent product launches including Phyrago for leukemias and Harliku for alkaptonuria.
Applied's Advanced Candidate: Applied Therapeutics' leading candidate is govorestat, an aldose reductase inhibitor currently in phase 3 trials for galactosemia and sorbitol dehydrogenase deficiency.
Market Position: The acquisition highlights the growing interest in rare disease treatments and the strategic alignment of both companies in addressing unmet medical needs.
Trade with 70% Backtested Accuracy
Analyst Views on APLT
About APLT
About the author
Cycle Extends Expiration Date for Applied Therapeutics Tender Offer
- Offer Extension: Cycle Group announces that AT2B has extended the expiration date of its tender offer for Applied Therapeutics from January 29, 2026, to February 2, 2026, indicating a sustained commitment to the acquisition that may enhance shareholder participation.
- Valid Tenders: As of January 29, 2026, approximately 75,895,437 shares of Applied have been validly tendered, representing about 49.21% of the outstanding shares, suggesting a high level of market acceptance for the transaction that could strengthen Cycle's market position.
- Acquisition Conditions: The successful execution of the offer is contingent upon fulfilling specific conditions, including the tender of a majority of the outstanding shares, reflecting Cycle's cautious and thorough approach to its acquisition strategy aimed at ensuring a smooth transaction completion.
- Transparency in Communication: Cycle has engaged MacKenzie Partners as the information agent to ensure shareholders receive necessary documents and information, enhancing transaction transparency and shareholder trust, which may encourage more shareholders to participate in the tender offer.
RF Industries Reports $22.7M Q4 Sales, Shares Surge 21.4%
- Strong Financial Performance: RF Industries reported fourth-quarter net sales of $22.7 million, a 23% increase from $18.5 million a year earlier, indicating robust market performance that is likely to boost investor confidence.
- Significant Net Income Growth: The company achieved a non-GAAP net income of $2.1 million in Q4, translating to 20 cents per diluted share, a substantial increase from $394,000 or 4 cents per share in the same quarter last year, reflecting enhanced profitability.
- Stock Price Surge: Following the earnings report, RF Industries' shares jumped 21.4% to $8.76 in pre-market trading, indicating strong market optimism regarding the company's future growth potential, which may attract more investor interest.
- Quarterly Growth Trend: Compared to $19.8 million in sales for Q3 of fiscal 2025, the fourth-quarter sales increased by 15%, demonstrating the company's effective strategies in expanding market share and enhancing product demand.
Quipt Home Medical to Sell for $3.65 per Share to Kingswood and Forager
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Quipt Home Medical Corp.'s sale for $3.65 per share, which may violate federal securities laws and impact shareholder rights.
- Merger Transaction Impact: The merger between Fifth Third Bancorp and Comerica Incorporated will result in Fifth Third shareholders owning approximately 73% of the combined entity, potentially altering shareholder control and corporate governance structures.
- Potential Payment Rights: Generation Bio Co. is being sold for $4.2913 per share, along with a non-transferable contingent value right, which could provide shareholders with additional potential payments, enhancing investment appeal.
- Legal Rights Protection: Halper Sadeh LLC offers free consultations to help shareholders understand their legal rights and options, aiming to secure increased consideration and additional disclosures for affected investors.
Reasons Why Applied Therapeutics (APLT) Is an Excellent 'Buy the Dip' Stock at This Time
Stock Performance: Applied Therapeutics Inc. (APLT) shares have dropped 46.8% over the past week, but a hammer chart pattern suggests potential support and a possible trend reversal.
Technical Analysis: The hammer pattern indicates that selling pressure may be exhausting, and if it appears at the bottom of a downtrend, it signals that bears might be losing control.
Earnings Outlook: Recent upward revisions in earnings estimates, with a 1.9% increase in the consensus EPS estimate, indicate that analysts expect better performance from APLT, enhancing its bullish prospects.
Zacks Rank: APLT holds a Zacks Rank of #2 (Buy), placing it in the top 20% of stocks based on earnings estimate trends, which historically correlates with positive stock performance.
Halper Sadeh Investigates A&B Sale to MW Group for $21.20 per Share
- Legal Investigation Initiated: Halper Sadeh LLC is investigating Alexander & Baldwin, Inc. (NYSE: ALEX) for its sale to MW Group and funds affiliated with Blackstone Real Estate and DivcoWest at $21.20 per share, potentially violating federal securities laws and fiduciary duties to shareholders.
- Shareholder Rights Protection: The law firm encourages A&B shareholders to understand their rights and options, potentially seeking increased consideration for shareholders or other relief measures to protect their interests.
- Merger Transaction Review: Halper Sadeh is also investigating Destination XL Group, Inc. (NASDAQ: DXLG) for its merger with FBB Holdings I, Inc., ensuring transparency and compliance throughout the transaction process.
- Potential Compensation Opportunities: The investigation extends to Applied Therapeutics, Inc. (NASDAQ: APLT), which is selling to Cycle Group Holdings Limited for $0.088 per share, with Halper Sadeh potentially advocating for additional compensation and disclosures for shareholders.
S&P 500 Declines 1%; Broadcom Reports Earnings Exceeding Expectations
U.S. Stock Market Performance: U.S. stocks declined, with the Nasdaq Composite dropping over 350 points, while the Dow and S&P 500 also experienced losses of 0.45% and 1.04%, respectively.
Broadcom's Strong Earnings: Broadcom Inc. reported fourth-quarter revenue of $18.02 billion, exceeding expectations, and announced a 10% increase in its quarterly cash dividend.
Notable Stock Movements: cbdMD Inc. shares surged 126% after compliance news, while Canopy Growth Corp. rose 38% on potential regulatory changes. Conversely, Applied Therapeutics Inc. fell 44% following acquisition news.
Global Market Trends: European shares declined, with the eurozone's STOXX 600 down 0.53%, while Asian markets closed higher, led by Japan's Nikkei gaining 1.37%.
Cycle Extends Expiration Date for Applied Therapeutics Tender Offer
- Offer Extension: Cycle Group announces that AT2B has extended the expiration date of its tender offer for Applied Therapeutics from January 29, 2026, to February 2, 2026, indicating a sustained commitment to the acquisition that may enhance shareholder participation.
- Valid Tenders: As of January 29, 2026, approximately 75,895,437 shares of Applied have been validly tendered, representing about 49.21% of the outstanding shares, suggesting a high level of market acceptance for the transaction that could strengthen Cycle's market position.
- Acquisition Conditions: The successful execution of the offer is contingent upon fulfilling specific conditions, including the tender of a majority of the outstanding shares, reflecting Cycle's cautious and thorough approach to its acquisition strategy aimed at ensuring a smooth transaction completion.
- Transparency in Communication: Cycle has engaged MacKenzie Partners as the information agent to ensure shareholders receive necessary documents and information, enhancing transaction transparency and shareholder trust, which may encourage more shareholders to participate in the tender offer.
RF Industries Reports $22.7M Q4 Sales, Shares Surge 21.4%
- Strong Financial Performance: RF Industries reported fourth-quarter net sales of $22.7 million, a 23% increase from $18.5 million a year earlier, indicating robust market performance that is likely to boost investor confidence.
- Significant Net Income Growth: The company achieved a non-GAAP net income of $2.1 million in Q4, translating to 20 cents per diluted share, a substantial increase from $394,000 or 4 cents per share in the same quarter last year, reflecting enhanced profitability.
- Stock Price Surge: Following the earnings report, RF Industries' shares jumped 21.4% to $8.76 in pre-market trading, indicating strong market optimism regarding the company's future growth potential, which may attract more investor interest.
- Quarterly Growth Trend: Compared to $19.8 million in sales for Q3 of fiscal 2025, the fourth-quarter sales increased by 15%, demonstrating the company's effective strategies in expanding market share and enhancing product demand.
Quipt Home Medical to Sell for $3.65 per Share to Kingswood and Forager
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Quipt Home Medical Corp.'s sale for $3.65 per share, which may violate federal securities laws and impact shareholder rights.
- Merger Transaction Impact: The merger between Fifth Third Bancorp and Comerica Incorporated will result in Fifth Third shareholders owning approximately 73% of the combined entity, potentially altering shareholder control and corporate governance structures.
- Potential Payment Rights: Generation Bio Co. is being sold for $4.2913 per share, along with a non-transferable contingent value right, which could provide shareholders with additional potential payments, enhancing investment appeal.
- Legal Rights Protection: Halper Sadeh LLC offers free consultations to help shareholders understand their legal rights and options, aiming to secure increased consideration and additional disclosures for affected investors.
Reasons Why Applied Therapeutics (APLT) Is an Excellent 'Buy the Dip' Stock at This Time
Stock Performance: Applied Therapeutics Inc. (APLT) shares have dropped 46.8% over the past week, but a hammer chart pattern suggests potential support and a possible trend reversal.
Technical Analysis: The hammer pattern indicates that selling pressure may be exhausting, and if it appears at the bottom of a downtrend, it signals that bears might be losing control.
Earnings Outlook: Recent upward revisions in earnings estimates, with a 1.9% increase in the consensus EPS estimate, indicate that analysts expect better performance from APLT, enhancing its bullish prospects.
Zacks Rank: APLT holds a Zacks Rank of #2 (Buy), placing it in the top 20% of stocks based on earnings estimate trends, which historically correlates with positive stock performance.
Halper Sadeh Investigates A&B Sale to MW Group for $21.20 per Share
- Legal Investigation Initiated: Halper Sadeh LLC is investigating Alexander & Baldwin, Inc. (NYSE: ALEX) for its sale to MW Group and funds affiliated with Blackstone Real Estate and DivcoWest at $21.20 per share, potentially violating federal securities laws and fiduciary duties to shareholders.
- Shareholder Rights Protection: The law firm encourages A&B shareholders to understand their rights and options, potentially seeking increased consideration for shareholders or other relief measures to protect their interests.
- Merger Transaction Review: Halper Sadeh is also investigating Destination XL Group, Inc. (NASDAQ: DXLG) for its merger with FBB Holdings I, Inc., ensuring transparency and compliance throughout the transaction process.
- Potential Compensation Opportunities: The investigation extends to Applied Therapeutics, Inc. (NASDAQ: APLT), which is selling to Cycle Group Holdings Limited for $0.088 per share, with Halper Sadeh potentially advocating for additional compensation and disclosures for shareholders.
S&P 500 Declines 1%; Broadcom Reports Earnings Exceeding Expectations
U.S. Stock Market Performance: U.S. stocks declined, with the Nasdaq Composite dropping over 350 points, while the Dow and S&P 500 also experienced losses of 0.45% and 1.04%, respectively.
Broadcom's Strong Earnings: Broadcom Inc. reported fourth-quarter revenue of $18.02 billion, exceeding expectations, and announced a 10% increase in its quarterly cash dividend.
Notable Stock Movements: cbdMD Inc. shares surged 126% after compliance news, while Canopy Growth Corp. rose 38% on potential regulatory changes. Conversely, Applied Therapeutics Inc. fell 44% following acquisition news.
Global Market Trends: European shares declined, with the eurozone's STOXX 600 down 0.53%, while Asian markets closed higher, led by Japan's Nikkei gaining 1.37%.
